Hui-Min Lin

Title: Hui-Min Lin: Innovator in Pharmaceutical Chemistry

Introduction

Hui-Min Lin is a notable inventor based in Cambridge, MA, specializing in pharmaceutical chemistry. He has made significant contributions to the field, particularly in the development of innovative treatments for various medical conditions. His work is characterized by a focus on oncogenic alterations and their implications in systemic diseases.

Latest Patents

Hui-Min Lin holds a patent for a novel dosing regimen of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine. This patent, which is aimed at treating indolent systemic mastocytosis, includes crystalline forms of the compound and its pharmaceutically acceptable salts. The patent also discloses pharmaceutical compositions, methods for treating disorders associated with oncogenic KIT and PDGFRA alterations, and methods for synthesizing the compound and its crystalline forms.

Career Highlights

Hui-Min Lin is currently associated with Blueprint Medicines Corporation, where he continues to advance his research and development efforts. His work has been instrumental in creating effective pharmaceutical solutions that address critical health issues.

Collaborations

Hui-Min Lin collaborates with esteemed colleagues, including Brenton Mar and Anthony L Boral, to enhance the impact of his research and to foster innovation within the pharmaceutical industry.

Conclusion

Hui-Min Lin's contributions to pharmaceutical chemistry and his innovative patent work exemplify his commitment to improving treatment options for patients. His ongoing research at Blueprint Medicines Corporation continues to pave the way for advancements in medical science.